We are
Towa International
We are the international hub of Towa Pharmaceutical, the leading company in the generics market in Japan. We are dedicated to the research, development, manufacturing, marketing, and distribution of generic and value-added medicines, with the goal of contributing to people’s health and generating genuine smiles.
Headquartered in Barcelona, we have an R&D center and pilot plant, as well as a production facility of over 35,000 m², making it one of the largest in Europe and the biggest for controlled-release products.
We operate through four independent yet complementary business units. These units address distinctcbusiness and regulatory needs: Towa US – Breckenridge Pharmaceutical, with offices in New Jersey; Towa EU (Towa Pharmaceutical Italy, Spain, and Portugal), with offices in Milan, Barcelona, and Lisbon; Towa 2B (worldwide); and the recently launched CMO/CDMO unit, which maximizes the potential of our R&D and manufacturing capabilities by offering them to our partners.
We are accredited by the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), SFDA (Saudi Food and Drug Authority), the PMDA certification from Japan’s health authorities, and the certification from the Department of Pharmacy of the Ministry of Health of the State of Libya.
With nearly 1,000 employees worldwide, we are consolidating our presence in the generics market and look forward to having you join us on this new journey.
1st and only Japanese
generics company with a direct presence in both Europe and the US
€0M+
in sales
0+
employees
0%+
of revenues invested in R&D
0
countries with direct presence
From Towa to the World Our journey began in 1951.
Towa Pharmaceutical was founded in Osaka, Japan, as a wholesaler and broker of pharmaceutical raw materials. The Towa Group contributes to people’s health by delivering high-quality products and services.
Through our corporate activities, we strive to be a company that is valued and trusted by patients, healthcare professionals, local communities, and beyond.
In 2020, Towa took a significant step toward internationalization by acquiring Pensa Pharma — a well-established generic medicines platform with a commercial presence in the US and the EU, as well as robust R&D and manufacturing capabilities.
This milestone marked the creation of what we are today: Towa International.